AQST
Aquestive Therapeutics, Inc. NASDAQ Listed Jul 25, 2018$4.23
Mkt Cap $420.1M
52w Low $2.12
38.9% of range
52w High $7.55
50d MA $4.14
200d MA $4.86
P/E (TTM)
-5.5x
EV/EBITDA
-11.3x
P/B
—
Debt/Equity
-3.9x
ROE
248.9%
P/FCF
-14.9x
RSI (14)
—
ATR (14)
—
Beta
1.53
50d MA
$4.14
200d MA
$4.86
Avg Volume
3.0M
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
30 Technology Drive · Warren, NJ 07059 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | AMC | -0.13 | -0.26 | -100.0% | 4.37 | -2.5% | -2.5% | -3.4% | -1.8% | -3.9% | -2.3% | — |
| Nov 5, 2025 | AMC | -0.11 | -0.14 | -27.3% | 6.00 | +8.0% | +2.2% | +0.7% | -7.0% | -5.2% | -7.0% | — |
| Aug 11, 2025 | AMC | -0.18 | -0.14 | +22.2% | 3.86 | +3.1% | -2.1% | +3.9% | +6.5% | +6.5% | +8.3% | — |
| May 12, 2025 | AMC | -0.17 | -0.24 | -41.2% | 2.85 | -10.2% | -19.6% | -22.1% | -16.5% | -16.5% | -14.0% | — |
| Mar 5, 2025 | AMC | -0.14 | -0.19 | -35.7% | 2.79 | -11.8% | -7.5% | -5.0% | -9.0% | -5.4% | +5.4% | — |
| Nov 4, 2024 | AMC | -0.12 | -0.13 | -8.3% | 5.15 | -2.9% | -7.6% | -1.6% | -1.4% | +6.0% | -1.6% | — |
| Aug 6, 2024 | AMC | -0.11 | -0.03 | +72.7% | 3.40 | +7.1% | +0.9% | -3.2% | +0.9% | +0.0% | +15.3% | — |
| May 7, 2024 | AMC | -0.09 | -0.17 | -88.9% | 3.38 | -5.9% | -8.6% | -2.7% | -8.6% | -3.3% | -5.3% | — |
| Mar 5, 2024 | AMC | -0.08 | -0.12 | -50.0% | 4.19 | -2.1% | +20.0% | +35.6% | +16.5% | +17.9% | +21.7% | — |
| Nov 6, 2023 | AMC | -0.11 | -0.03 | +72.7% | 1.63 | +1.8% | +4.9% | +2.5% | +4.9% | +3.1% | +3.1% | — |
| Aug 7, 2023 | AMC | -0.11 | -0.10 | +9.1% | 2.05 | +5.9% | -5.4% | -2.0% | -4.9% | -5.4% | -9.8% | — |
| May 2, 2023 | AMC | -0.10 | 0.11 | +210.0% | 1.39 | +9.4% | +20.9% | +41.0% | +46.8% | +61.9% | +67.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 24 | Oppenheimer | Reiterates | Outperform | $8 | $4.07 | $4.10 | +0.7% | +0.2% | +0.7% | +0.5% | -0.5% | +0.7% |
| Nov 7 | Piper Sandler | Maintains | Overweight → Overweight | — | $6.13 | $6.41 | +4.6% | -1.5% | -9.0% | -7.2% | -9.0% | -13.5% |
| Oct 9 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.20 | $6.34 | +2.3% | +7.9% | +5.5% | +7.4% | +11.0% | +18.4% |
| Sep 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $5.42 | $5.50 | +1.5% | -7.6% | -8.1% | -10.0% | -8.7% | -6.8% |
| Jun 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.54 | $3.50 | -1.1% | -5.4% | -4.0% | -8.2% | -7.1% | -9.3% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.22 | $2.23 | +0.5% | +7.2% | +7.2% | +10.4% | +7.7% | +2.3% |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.86 | $2.80 | -2.1% | +6.3% | +0.3% | -5.2% | -8.4% | -17.1% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.65 | $2.61 | -1.5% | -4.2% | -0.4% | +10.9% | +2.6% | +7.2% |
| Mar 7 | Lake Street | Maintains | Buy → Buy | — | $2.58 | $2.58 | +0.0% | +2.7% | -1.6% | +2.3% | +14.0% | +5.4% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.64 | $3.56 | -2.2% | +0.3% | -1.4% | -3.3% | +0.5% | -3.3% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.46 | $5.54 | +1.5% | -7.1% | -8.6% | -11.5% | -16.3% | -18.7% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.76 | $4.98 | +4.6% | +6.5% | +6.7% | +14.7% | +6.5% | +4.8% |
| Oct 25 | Leerink Partners | Maintains | Outperform → Outperform | — | $5.48 | $5.56 | +1.5% | +0.2% | +0.2% | +3.3% | +2.9% | +0.2% |
| Oct 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.48 | $5.56 | +1.5% | +0.2% | +0.2% | +3.3% | +2.9% | +0.2% |
| Oct 8 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.85 | $4.87 | +0.4% | +1.4% | -1.9% | -3.1% | +0.8% | -0.2% |
| Sep 30 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.72 | $4.76 | +0.8% | +5.5% | +0.8% | +1.5% | -0.8% | +4.9% |
| Sep 30 | Leerink Partners | Maintains | Outperform → Outperform | — | $4.72 | $4.76 | +0.8% | +5.5% | +0.8% | +1.5% | -0.8% | +4.9% |
| Sep 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.72 | $4.76 | +0.8% | +5.5% | +0.8% | +1.5% | -0.8% | +4.9% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.92 | $4.01 | +2.3% | -1.5% | +5.1% | +8.2% | +8.7% | +10.5% |
| Aug 12 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.43 | $3.46 | +0.9% | -0.9% | +14.3% | +12.5% | +20.1% | +23.6% |
| Jul 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.45 | $3.56 | +3.2% | +10.7% | +10.7% | +10.1% | +11.3% | +4.1% |
| Jun 26 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.31 | $2.31 | +0.0% | +4.8% | +12.1% | +12.6% | +6.1% | +4.8% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.95 | $2.98 | +1.0% | +1.4% | -4.7% | -6.8% | -6.4% | -4.7% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.09 | $3.10 | +0.3% | +6.5% | +0.0% | +5.8% | +3.6% | +4.2% |
| Apr 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.74 | $3.59 | -4.0% | -10.2% | -9.9% | -12.3% | -5.9% | -6.4% |
| Apr 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.16 | $4.19 | +0.7% | -1.4% | -2.2% | -1.7% | -2.2% | -1.7% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.09 | $6.23 | +2.3% | -9.5% | -12.3% | -25.9% | -28.1% | -28.1% |
| Mar 15 | JMP Securities | Maintains | Outperform → Outperform | — | $5.25 | $5.41 | +3.0% | +16.0% | +5.0% | +1.7% | -14.1% | -16.6% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.88 | $5.02 | +2.9% | +1.2% | +4.5% | +11.5% | +7.6% | +24.8% |
| Mar 7 | Wedbush | Maintains | Outperform → Outperform | — | $5.03 | $5.12 | +1.8% | +12.9% | -3.0% | -1.8% | +1.4% | +8.2% |
| Mar 7 | Lake Street | Maintains | Buy → Buy | — | $5.03 | $5.12 | +1.8% | +12.9% | -3.0% | -1.8% | +1.4% | +8.2% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.71 | $1.74 | +1.8% | -2.3% | +0.0% | -1.8% | -1.8% | -5.3% |
| Oct 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.32 | $1.33 | +0.8% | +6.1% | +3.4% | +8.3% | +16.7% | +31.1% |
| Oct 10 | Wedbush | Maintains | Outperform → Outperform | — | $1.32 | $1.33 | +0.8% | +6.1% | +3.4% | +8.3% | +16.7% | +31.1% |
| Sep 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.63 | $1.63 | +0.0% | -3.1% | -8.0% | -6.1% | -6.7% | -8.0% |
| Sep 22 | Wedbush | Maintains | Outperform → Outperform | — | $1.63 | $1.63 | +0.0% | -3.1% | -8.0% | -6.1% | -6.7% | -8.0% |
| Sep 21 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.71 | $1.67 | -2.3% | -4.7% | -7.6% | -12.3% | -10.5% | -11.1% |
| Jul 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.92 | $2.00 | +4.2% | +14.1% | +16.7% | +13.0% | +13.5% | +8.9% |
| Jun 30 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.59 | $1.59 | +0.0% | +3.8% | +1.3% | +4.4% | +6.9% | +4.4% |
| Jun 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.05 | $2.03 | -1.0% | -1.5% | -7.8% | -10.7% | -19.0% | -19.0% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.26 | $2.22 | -1.8% | -4.4% | -0.9% | -4.0% | -4.9% | -6.2% |
| Mar 9 | Wedbush | Upgrade | Neutral → Outperform | — | $0.85 | $0.86 | +1.2% | -4.7% | -6.6% | -7.6% | -11.2% | -14.7% |
| Nov 4 | Alliance Global Partners | Maintains | Buy → Buy | — | $0.86 | $0.85 | -1.4% | +1.5% | +6.0% | +5.5% | +4.9% | +17.1% |
| Sep 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.31 | $1.30 | -0.8% | -4.6% | +12.2% | +12.2% | +11.5% | +9.9% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.73 | $1.75 | +1.2% | -7.5% | -13.3% | -18.5% | -11.6% | -17.3% |
| Jun 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.71 | $0.71 | +0.6% | +1.4% | +1.0% | +7.7% | +4.8% | +6.1% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.03 | $1.03 | +0.0% | -3.5% | -5.1% | -7.8% | -6.8% | -13.9% |
| Sep 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.61 | $5.03 | -33.9% | -34.7% | -42.0% | -36.2% | -38.9% | -38.6% |
| Sep 28 | RBC Capital | Maintains | Outperform → Outperform | — | $7.61 | $5.03 | -33.9% | -34.7% | -42.0% | -36.2% | -38.9% | -38.6% |
| May 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.15 | $6.53 | +6.2% | -6.5% | -16.1% | -17.2% | -18.9% | -20.8% |
No insider trades available.
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Aquestive secured FDA clarification on critical study designs for Anaphylm, reducing development risk and supporting its Q3 2026 resubmission timeline, potentially unlocking emergency epinephrine market opportunity.
Mar 30
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Aquestive Therapeutics' executive departure signals potential leadership instability that could impact strategic direction and investor confidence in the biotech company's near-term operational execution.
Mar 20
8-K · 1.01
!! High
Aquestive Therapeutics, Inc. -- 8-K 1.01: Material Agreement
Aquestive Therapeutics issued warrants to Segregated Liability Company, expanding its capital structure and potentially diluting existing shareholders while providing the company with additional financing flexibility.
Mar 4
8-K · 7.01
! Medium
Aquestive Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Aquestive Therapeutics is presenting updated investor materials at institutional meetings, providing guidance that may be revised through future SEC filings.
Feb 26
8-K · 7.01
! Medium
Aquestive Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Aquestive Therapeutics received FDA feedback on Anaphylm with only minor packaging and administration deficiencies, positioning the company favorably for potential anaphylaxis treatment approval.
Feb 2
Data updated apr 24, 2026 6:41pm
· Source: massive.com